NLST低剂量CT筛查的患者层面轨迹与结局
基于美国国家肺癌筛查试验(NLST)的二次分析,按每次LDCT检查与按患者两种层面统计下游评估、侵入性操作及并发症,并比较合并与不合并COPD者的结局。结果显示患者层面结局高于检查层面,COPD患者接受诊断性检查、侵入性操作、发生并发症及确诊肺癌的风险均更高。
要点
- 向患者沟通筛查风险受益时应采用患者层面数据而非单次检查数据
- 合并COPD者诊断性检查、侵入性操作及并发症风险更高,但肺癌检出也更多
- COPD患者筛查的风险与受益可能同时增加,需个体化共同决策
核心结论
- NLST提供了可用于指导共同决策的患者层面数据,合并COPD等患者的筛查风险受益比可能显著不同。
研究设计与样本
- 对NLST数据的二次分析,共分析75,138次LDCT检查及24,453例接受LDCT筛查的患者。
主要发现
- 14.2%的LDCT检查导致诊断性检查、1.5%导致侵入性操作,0.3%出现操作相关并发症、0.1%出现严重并发症。
- 24,453例筛查患者中30.5%接受诊断性检查、4.2%接受侵入性操作,0.9%出现操作相关并发症、0.3%出现严重并发症。
- COPD患者诊断性检查aOR 1.29(P < .01)、侵入性操作aOR 1.41(P < .01)、并发症aOR 1.83(P < .01)、严重并发症aOR 1.78(P = .01)、肺癌诊断aOR 1.43(P < .01)。
临床怎么用
- 与患者进行LDCT筛查共同决策时,可引用患者层面的下游评估与并发症概率。
- 对合并COPD者应说明其检查、侵入性操作及并发症风险更高,同时肺癌检出可能增加。
局限性
- COPD依据自我报告定义。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Shared decision-making is an essential element of low-dose CT (LDCT) screening for lung cancer. Understanding patient-level outcomes from the National Lung Screening Trial (NLST) is critical to effectively communicate risks and benefits of screening to patients. METHODS: We performed a secondary analysis of data collected in the NLST. We determined outcomes of each LDCT scan performed in the NLST (downstream evaluation, complications, lung cancer diagnoses), and compared outcomes at the test level with outcomes calculated at the patient level for those randomized to LDCT screening. To assess the impact of COPD on patient outcomes, we compared outcomes among patients with and without COPD. RESULTS: Of 75,138 LDCT scans, 14.2% led to a diagnostic study and 1.5% to an invasive procedure, with 0.3% of LDCT scans resulting in a procedure-related complication and 0.1% in a serious complication. Among 24,453 patients who underwent LDCT screening, 30.5% underwent a diagnostic study and 4.2% an invasive procedure, with 0.9% of screened patients experiencing a procedure-related complication and 0.3% a serious complication. Patients with COPD (defined by self-report) were more likely to need a diagnostic study (adjusted OR [aOR], 1.29; P < .01) and an invasive procedure (aOR, 1.41; P < .01) and more likely to experience a complication (aOR, 1.83; P < .01) and a serious complication (aOR, 1.78; P = .01). Patients with COPD also were more likely to be diagnosed with lung cancer (aOR, 1.43; P < .01). CONCLUSIONS: We provide important patient-level data from the NLST that can be used to guide shared decision-making. The risk-to-benefit ratio of screening may vary significantly in some patients, such as those with COPD, in whom both risks and benefits of screening may be increased.
引用
- Iaccarino JM, Silvestri GA, Wiener RS, et al. Patient-Level Trajectories and Outcomes After Low-Dose CT Screening in the National Lung Screening Trial. Chest. 2019. PMID: 31283920. doi:10.1016/j.chest.2019.06.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。